Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Shares Issued (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Shares Issued data on record, last reported at $145000.0 in Q4 2025.

  • For Q4 2025, Shares Issued rose 100.15% year-over-year to $145000.0; the TTM value through Dec 2025 reached $462000.0, down 19.51%, while the annual FY2025 figure was $462000.0, 19.51% down from the prior year.
  • Shares Issued reached $145000.0 in Q4 2025 per TRDA's latest filing, down from $317000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $99.8 million in Q2 2024 and bottomed at -$99.0 million in Q4 2024.
  • Average Shares Issued over 4 years is $186000.0, with a median of $195000.0 recorded in 2022.
  • The widest YoY moves for Shares Issued: up 38730.35% in 2024, down 9993.51% in 2024.
  • A 4-year view of Shares Issued shows it stood at $195000.0 in 2022, then soared by 413.33% to $1.0 million in 2023, then plummeted by 9993.51% to -$99.0 million in 2024, then soared by 100.15% to $145000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $145000.0 in Q4 2025, $317000.0 in Q3 2025, and -$350000.0 in Q2 2025.